Columbus, OHNCT07356245Now EnrollingIRB Ready

T-cell Lymphoma Clinical Trial in Columbus, OH

Access cutting-edge t-cell lymphoma treatment through this phase 2 clinical trial at a research site in Columbus. Study-provided care at no cost to qualified participants.

Sponsored by Jonathan Brammer

Quick Self-Assessment

See if you qualify for this Columbus location

Preparing your pre-screening questions…

Expert Care in Columbus

Access t-cell lymphoma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related t-cell lymphoma treatment provided free

Apply for This Columbus Location

Check if you qualify for this t-cell lymphoma clinical trial in Columbus, OH

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Columbus

    Convenient for OH residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Columbus site if eligible
  4. 4Begin participation

About This T-cell Lymphoma Study in Columbus

This phase II trial tests how well ruxolitinib as a maintenance medication works to prevent relapse and graft-versus-host disease (GVHD) for patients who have undergone stem cell transplantation for T-cell lymphoma. GVHD is a common problem that may occur after a blood stem cell transplant. The "graft" is the donor blood cells that patients get during the transplant. The "host" is the person receiving the cells. GVHD is when the donor graft attacks and damages some of the transplant recipient's tissues. Ruxolitinib is a type of drug called a Janus kinase (JAK) inhibitor which works by decreasing the immune response of cells in the body. It is also a cancer growth blocker that blocks the growth factors that trigger the cancer cells to divide and grow. Ruxolitinib works by blocking a gene, called JAK2, that is important in the production of cancer cells.

Sponsor: Jonathan Brammer

Who Can Participate

Inclusion Criteria

Adult patients with T-cell lymphoma \[PTCL (all subtypes), T-PLL, ATLL, and CTCL (all subtypes)\] in partial or complete remission between day +35 and +120 from auto-SCT or allo-SCT
Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less
Adequate hematologic function defined by absolute neutrophil count (ANC) \> 1000/mm3 without granulocyte colony-stimulating factor (G-CSF) for at least 3 days, platelets \> 50K/mm3 without transfusion for at least 3 days and hemoglobin (Hb) \> 8.0 g/dL without transfusion for at least 3 days.
Adequate organ function defined by total Bilirubin \< 1.5 x ULN, alanine aminotransferase (ALT) \</= 3 x ULN, CKD-EPI eGFR ≥ 30 ml/min, SpO2 \> 92% without supplemental oxygen.
Able to tolerate oral or enteral medications.
Men and women of reproductive potential must agree to follow accepted birth control methods for the duration of the study. Female subject is either post-menopausal or surgically sterilized or willing to use an acceptable method of birth control (i.e., a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study. Male subject agrees to use an acceptable method for contraception for the duration of the study.
Able to read and sign informed consent.

Exclusion Criteria

Anaplastic lymphoma kinase (ALK)+ or Dual specificity 22 (DUSP22)+ ALCL with low international prognostic index (IPI) score (\<2) in first complete remission.
Progressive disease or any other systemic therapy post-SCT (radiation allowed)
Disease progression to Ruxolitinib previously
GvHD requiring systemic therapy.
Active uncontrolled infections.
Active thrombotic active microangiopathy requiring therapy.
History of veno-occlusive disorder post-transplant
Use of platelets antiaggregant or anticoagulants deemed to be unsafe to be held in case of thrombocytopenia.
History of life-threatening bleeding defined as any bleeding that required invasive procedures or involving central nervous system.
Pregnancy (positive Beta HCG test in a woman with childbearing potential defined as not postmenopausal for 12 months or no previous surgical sterilization) or currently breast-feeding. Pregnancy testing is not required for post-menopausal or surgically sterilized women.
Uncontrolled Hepatitis B/C, HIV, tuberculosis, mycobacterium, or fungal infection.
Exposure to other investigational drugs within 4 weeks before enrollment.
Grade ≥ 3 non-hematologic toxicity from SCT that has not resolved to grade ≤ 2.
Myocardial infarction or stroke within 1 year of study entry.
Any uncontrolled medical problem at the discretion of the investigator that would pose a risk to the patient.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Columbus?

Yes, this clinical trial (NCT07356245) has an active research site in Columbus, OH that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

T-cell Lymphoma Treatment Options in Columbus, OH

If you're searching for t-cell lymphoma treatment options in Columbus, OH, this clinical trial (NCT07356245) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Columbus research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced t-cell lymphoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all t-cell lymphoma clinical trials near you to find additional studies recruiting in your area.

More Lymphoma Trials in Columbus, OH

See all lymphoma clinical trials recruiting in Columbus — not just this study.

Browse Lymphoma Trials in Columbus →

Browse More Trials by Condition

Lymphoma TrialsPulmonary Hypertension TrialsPeripheral T-Cell Lymphoma TrialsAll Conditions →

Ready to Join in Columbus?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Columbus, OH